CHINA TO SELL PHARMA PLANTS
The authorities in China's Sichuan Province have announced plans to sell off a number of state-owned pharmaceutical enterprises that either have high sales or are profitable and have great potential for development, reports the Beijing Review.
Foreigners will be able to purchase the enterprises outright, participate in joint investments or invest as shareholders. The enterprises will be sold in a number of ways, with the main stipulation being that the purchaser or investor must retain the existing workforce when an enterprise is purchased outright.
Further information about the proposal is expected to be released at the '94 Sichuan Investment Talks, to be held June 28-July 1 in the provincial capital of Chengdu.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze